Home » Newsletters » BioWorld Science

BioWorld Science

June 19, 2014

View Archived Issues

Results from phase I trial of PF-06438179, a biosimilar to infliximab

ABP-501 proves equivalent to adalimumab in healthy volunteers

NNC-0151-0000 development halted, second-generation compound shows improved profile

Selexipag meets endpoint in pivotal phase III study in PAH

Inovio Pharmaceuticals expands license agreement with the University of Pennsylvania

Phase III perampanel trial meets primary endpoint in primary generalized tonic-clonic seizures

Isis Pharmaceuticals earns milestone payment under Biogen Idec collaboration

PsiOxus initiates phase I/II study of enadenotucirev for ovarian cancer

GW Pharmaceuticals reports expanded-access data for Epidiolex

Eculizumab receives U.S. orphan drug designation for myasthenia gravis

FDA award orphan drug designation to COTI-2 for ovarian cancer

Senhwa Biosciences begins phase I/II trial of CX-4945

Galapagos provides progress update on R&D programs

Bioequivalence of LY-2963016 to originator insulin glargine

GlaxoSmithKline presents new IFN-alpha inducers

GlaxoSmithKline describe novel DGAT1 inhibitors

Novel phosphodiesterase PDE10A inhibitors synthesized at Merck & Co.

Piramal Enterprises patents new proinflammatory cytokine inhibitors

Enrollment complete in phase IIa trial of GALE-301 immunotherapy in gynecological cancer

New IDO inhibitors prepared by Vertex Pharmaceuticals

Immunomodulator HMPL-523 enters first-in-human trial

Selecta Biosciences outlines pipeline progress and reveals new product candidate

Endocyte regains rights to vintafolide

Allergan acknowledges second unsolicited exchange offer from Valeant

BMS-817399 fails to improve rheumatoid arthritis in phase II proof-of-concept study

Takeda terminates development of orteronel for prostate cancer

Boehringer Ingelheim and Lilly resubmit empagliflozin NDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...